EUVIMEDOpdag EUVIMED
VergleichsstudieBeobachtungsstudieOpen access · CC BY 4.0

Real-World Long-term Comparisons of Rituximab versus Calcineurin Inhibitors for Membranous Nephropathy in the Cure Glomerulonephropathy Study

Meghan K Gerety iD, Vivek Charu iD, Madison Simmons iD, Nicholas J Seewald iD, Dorey A Glenn iD, Douglas E Schaubel iD, Abigail R Smith iD, Dhruti Chen iD, Louis-Philippe Laurin iD, Michelle Denburg, Lawrence B Holzman, Laurence H Beck iD and 2 more

Kidney360 · 2026-10 · 7 (10) · 2324-2334

DOI: 10.34067/kid.0000001265 ↗

At a glance

Vergleichsstudie in Kidney360, published online on 2026-07-10. Written by Meghan K Gerety and 13 co-authors. Institution: Division of Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philad…. Major MEDLINE topics: Glomerulonephritis, Membranous, Rituximab, Calcineurin Inhibitors, Immunosuppressive Agents. 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Key Points Comparative treatment effects for rituximab and calcineurin inhibitors on real-world long-term outcomes were estimated. Rituximab was associated with better preservation of long-term kidney function in Cure Glomerulonephropathy patients with membranous nephropathy. Treatments captured real-world prescribing practices, and observations pertain to a broad, pragmatic population relevant to clinical practice.

Background

Clinical trials in rare glomerular disease may establish short-term treatment efficacy but are limited by small sample sizes and short study duration. Observational data are needed to assess longer-term outcomes and can provide insights into real-world prescribing practices. This study applied modern statistical methods to real-world data from the Cure Glomerulonephropathy network to compare the effectiveness of rituximab and calcineurin inhibitors on long-term primary membranous nephropathy outcomes.

Methods

CureGN participants with biopsy-confirmed primary membranous nephropathy who initiated either of the two treatments at least 6 months after any previous immunosuppressant exposure were eligible. Inverse probability-of-treatment weighting balanced covariates at treatment initiation. Inverse probability-of-censoring weights accounted for censoring individuals if another immunosuppressant was started during follow-up. Outcomes included time from treatment initiation to composite kidney disease progression (40% decline in eGFR, KRT, or eGFR

Subjects

MeSH terms (MEDLINE)

Glomerulonephritis, MembranousRituximabCalcineurin InhibitorsImmunosuppressive AgentsHumansFemaleMaleMiddle AgedTreatment OutcomeDisease ProgressionAdultGlomerular Filtration RateProteinuriaRecurrence

Author keywords

biostatisticscohort studiesepidemiological methodsepidemiology and outcomesglomerular diseasesimmunosuppressionmembranous nephropathyoutcomesproteinuria

Substances

RituximabCalcineurin InhibitorsImmunosuppressive Agents

Authors and institutions

  • Division of Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Department of Medicine, Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California.
  • Department of Pathology, Stanford University School of Medicine, Stanford, California.
  • Howard University, Washington, DC.
  • Division of Nephrology and Hypertension, UNC Kidney Center, Chapel Hill, North California.
  • Division of Biostatistics and Informatics, Department of Preventive Medicine, Northwestern University, Chicago, Illinois.

ORCID profiles: Meghan K Gerety, Vivek Charu, Madison Simmons, Nicholas J Seewald, Dorey A Glenn, Douglas E Schaubel, Abigail R Smith, Dhruti Chen, Louis-Philippe Laurin, Laurence H Beck, Jarcy Zee

Funding

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

Gerety, M. K., Charu, V., Simmons, M., Seewald, N. J., Glenn, D. A., Schaubel, D. E., Smith, A. R., Chen, D., Laurin, L. P., Denburg, M., Holzman, L. B., Beck, L. H., Mariani, L. H., & Zee, J. (2026). Real-World Long-term Comparisons of Rituximab versus Calcineurin Inhibitors for Membranous Nephropathy in the Cure Glomerulonephropathy Study. Kidney360, 7(10), 2324-2334. https://doi.org/10.34067/kid.0000001265

Vancouver

Gerety MK, Charu V, Simmons M, Seewald NJ, Glenn DA, Schaubel DE, et al. Real-World Long-term Comparisons of Rituximab versus Calcineurin Inhibitors for Membranous Nephropathy in the Cure Glomerulonephropathy Study. Kidney360. 2026;7(10):2324-2334. doi:10.34067/kid.0000001265

BibTeX
@article{Gerety2026,
  author = {Gerety, Meghan K and Charu, Vivek and Simmons, Madison and Seewald, Nicholas J and Glenn, Dorey A and Schaubel, Douglas E and Smith, Abigail R and Chen, Dhruti and Laurin, Louis-Philippe and Denburg, Michelle and Holzman, Lawrence B and Beck, Laurence H and Mariani, Laura H and Zee, Jarcy},
  title = {Real-World Long-term Comparisons of Rituximab versus Calcineurin Inhibitors for Membranous Nephropathy in the Cure Glomerulonephropathy Study},
  journal = {Kidney360},
  year = {2026},
  volume = {7},
  number = {10},
  pages = {2324--2334},
  doi = {10.34067/kid.0000001265}
}
Start for free →